This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Some cookies on this site are essential, and the site won't work as expected without them. These cookies are set when you submit a form, login or interact with the site by doing something that goes beyond clicking on simple links.

We also use some non-essential cookies to anonymously track visitors or enhance your experience of the site. If you're not happy with this, we won't set these cookies but some nice features of the site may be unavailable.


Keyvisual giving


Phase III Clinical Trial.

Phase III Clinical Trial COMPETE with n.c.a. 177Lu-Edotreotide (Solucin®) in Cancer Patients with GEP-NET compared to mTOR inhibitor Everolimus.

View details >>

ITM. Who we are and what we do.

Do you want to learn about ITM’s #PrecisionOncology approach? Are you interested in why we enjoy our work?
Or do you simply want to know who we are and what #TargetedRadionuclideTherapy is?
Enjoy finding your answers in this video!

Watch the Video >>

Future-oriented and long-term alliance with Endocyte for the further expansion of targeted radioligand therapy with no-carrier-added Lutetium-177 for…

Read more

Funds will support ITM’s research and development strategy for cancer treatments

Financing by EU bank is provided under Investment Plan for Europe

Read more

ITM wins German Medical Award in the category “Medical Innovation Product” for outstanding patient benefit and advanced treatment approach with…

Read more

Find challenging opportunities within the ITM Group. Our employees are a key success factor, as each individual contributes to the overall success of the Company through his/her work ...

Join the ITM Team >>